89Bio is a biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders.
89bio was founded in 2018 by Michael Hayden.
1282 health care and life sciences companies are in the directory, 519 of them in the same 11-50 employee range and 43 based in San Francisco Bay Area.
89bio may be growing as it has initiated a Phase III trial for its MASH drug, which is a significant step in the drug development process and indicates progress in its pipeline. The initiation of a Phase III trial typically involves a substantial investment in research and development, suggesting that 89bio is allocating resources towards the advancement of its product. Furthermore, the company's aim to stand out in a growing field implies that there is an expanding market for its potential product, which could lead to increased revenue opportunities upon successful completion and approval of the trial.
“Roche is committed to making a contribution to areas of huge unmet need and societal burden through transformative science like in cardiovascular and metabolic diseases” 89bio.com
Founded in 2018, 89bio works in biopharma, biotechnology and pharmaceutical from San Francisco Bay Area and has 11-50 employees. It has raised $773.2 million over 7 rounds and its website drew about 1,914 visits in the latest month measured.
501-1,000 employees · abzena.com
501-1,000 employees · apcerls.com
1-10 employees · 101therapeutics.com
1-10 employees · abbiosciences.com
1-10 employees · abeomics.com
11-50 employees · 3tbiosciences.com
11-50 employees · alxoncology.com
11-50 employees · actuatetherapeutics.com
11-50 employees · amirasrl.com
11-50 employees · advancells.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.